-
EP4523690
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4523690
| EP4523690 - COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF MEK INHIBITOR COMPRISING ARIPIPRAZOLE AS ACTIVE INGREDIENT [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.02.2025 Database last updated on 09.04.2026 | |
| Former | The international publication has been made Status updated on 17.11.2023 | Most recent event Tooltip | 12.03.2026 | Supplementary search report | published on 08.04.2026 [2026/15] | Applicant(s) | For all designated states Korea Institute of Radiological & Medical Sciences (Gongneung-dong) 75, Nowon-ro Nowon-gu Seoul 01812 / KR | [2025/12] | Inventor(s) | 01 /
LIM, Young Bin Seoul 01745 / KR | 02 /
LEE, Hae June Seoul 04978 / KR | 03 /
KIM, Kwang Seok Seoul 01747 / KR | 04 /
LEE, Soo Ho Daegu 41522 / KR | [2025/12] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2025/12] | Application number, filing date | 23803834.3 | 10.05.2023 | [2025/12] | WO2023KR06334 | Priority number, date | KR20220057027 | 10.05.2022 Original published format: KR 20220057027 | KR20230057628 | 03.05.2023 Original published format: KR 20230057628 | [2025/12] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023219411 | Date: | 16.11.2023 | Language: | KO | [2023/46] | Type: | A1 Application with search report | No.: | EP4523690 | Date: | 19.03.2025 | Language: | EN | [2025/12] | Search report(s) | International search report - published on: | KR | 16.11.2023 | (Supplementary) European search report - dispatched on: | EP | 11.03.2026 | Classification | IPC: | A61K31/496, A61K31/519, A61K31/4184, A61K31/4523, A61K45/06, A61P35/00, A61P35/04, A23L33/10 | [2026/15] | CPC: |
A61P35/00 (EP,US);
A61K31/496 (EP,US);
A23L33/10 (EP);
A61K31/4184 (EP,US);
A61K31/4523 (EP,US);
A61K31/519 (EP,US);
| C-Set: |
A61K31/4184, A61K2300/00 (EP);
A61K31/4523, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP) |
| Former IPC [2025/12] | A61K31/496, A61K31/519, A61K45/06, A61P35/00, A23L33/10, A61P35/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/12] | Title | German: | ZUSAMMENSETZUNG ZUR VERBESSERUNG DER ANTIKREBSWIRKUNG EINES MEK-HEMMERS MIT ARIPIPRAZOL ALS WIRKSTOFF | [2025/12] | English: | COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF MEK INHIBITOR COMPRISING ARIPIPRAZOLE AS ACTIVE INGREDIENT | [2025/12] | French: | COMPOSITION DESTINÉE À RENFORCER L'EFFET ANTICANCÉREUX D'UN INHIBITEUR DE MEK COMPRENANT DE L'ARIPIPRAZOLE EN TANT QUE PRINCIPE ACTIF | [2025/12] | Entry into regional phase | 22.11.2024 | Translation filed | 22.11.2024 | National basic fee paid | 22.11.2024 | Search fee paid | 22.11.2024 | Designation fee(s) paid | 22.11.2024 | Examination fee paid | Examination procedure | 22.11.2024 | Amendment by applicant (claims and/or description) | 22.11.2024 | Examination requested [2025/12] | Fees paid | Renewal fee | 19.05.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y] KEITH T. FLAHERTY ET AL: "Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 367, no. 2, 12 July 2012 (2012-07-12), pages 107 - 114, XP055131678, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1203421 [Y] 1-9 * abstract * * figure 1 * DOI: http://dx.doi.org/10.1056/NEJMoa1203421 | [Y] JAAFAR BENNOUNA ET AL: "A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 29, no. 5, 2 February 2010 (2010-02-02), pages 1021 - 1028, XP019943330, ISSN: 1573-0646, DOI: 10.1007/S10637-010-9392-8 [Y] 1-9 * abstract * DOI: http://dx.doi.org/10.1007/s10637-010-9392-8 | International search | [A] KR20220036878 (KOREA INST RADIOLOGICAL & MEDICAL SCIENCES et al.) [A] 1-9 * See abstract; and claims 1-9. * | [A] KR20200111386 (RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV et al.) [A] 1-9 * See entire document. * | [A] KR20170026115 (UNIV SUNGKYUNKWAN RES & BUS et al.) [A] 1-9 * See entire document. * | [A] KIM JI YEONG, TAE IN HWAN, LEE BYUNG-MU, KIM HYUNG SIK, YOON SUNGPIL: "Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 38, no. 9, 1 September 2018 (2018-09-01), GR , pages 5101 - 5108, XP093106855, ISSN: 0250-7005, DOI: 10.21873/anticanres.12830 [A] 1-9 * See entire document. * DOI: http://dx.doi.org/10.21873/anticanres.12830 | [A] SHUHEI SUZUKI, MASASHI OKADA, KENTA KURAMOTO, HIROYUKI TAKEDA, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, : "Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 36, no. 10, 12 October 2016 (2016-10-12), GR , pages 5153 - 5162, XP055405053, ISSN: 0250-7005, DOI: 10.21873/anticanres.11085 [A] 1-9 * See entire document. * DOI: http://dx.doi.org/10.21873/anticanres.11085 | [A] BADRAN ADNAN, TUL-WAHAB ATIA, ZAFAR HUMAIRA, MOHAMMAD NAYAB, IMAD REHAN, ASHFAQ KHAN MARIAM, BAYDOUN ELIAS, CHOUDHARY M. IQBAL: "Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro", PLOS ONE, vol. 15, no. 8, 23 August 2020 (2020-08-23), pages e0235676, XP093106858, DOI: 10.1371/journal.pone.0235676 [A] 1-9 * See entire document. * DOI: http://dx.doi.org/10.1371/journal.pone.0235676 | [A] KIM MI SEON, BYONG CHUL YOO, WOO SEOK YANG, SANG YUN HAN, DEOK JEONG, JUN MIN SONG, KYUNG HEE KIM, ADITHAN ARAVINTHAN, JI HYE KIM: "Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action", ONCOTARGET., vol. 9, no. 5, 1 January 2018 (2018-01-01), pages 5979 - 5992, XP093106860, DOI: 10.18632/oncotarget.23192 [A] 1-9 DOI: http://dx.doi.org/10.18632/oncotarget.23192 |